181 related articles for article (PubMed ID: 33690015)
1. Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
Forest F; Casteillo F; Da Cruz V; Yvorel V; Picot T; Vassal F; Tiffet O; Péoc'h M
Lung Cancer; 2021 May; 155():1-9. PubMed ID: 33690015
[TBL] [Abstract][Full Text] [Related]
2. Solid histological component of adenocarcinoma might play an important role in PD-L1 expression of lung adenocarcinoma.
Miyazawa T; Morikawa K; Otsubo K; Sakai H; Kimura H; Chosokabe M; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
Thorac Cancer; 2022 Jan; 13(1):24-30. PubMed ID: 34811933
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays: Impact of the Architecture Pattern and the Number of Cores.
Gagné A; Enlow W; Pigeon MA; Orain M; Turcotte S; Bossé Y; Joubert P
Am J Surg Pathol; 2018 May; 42(5):687-694. PubMed ID: 29309297
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
Cai Y; Wu H; Shi X; Dong Y; Chang X; Zhang L; Zhou L; Su D; Yang M
BMC Cancer; 2020 Feb; 20(1):148. PubMed ID: 32093629
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing.
Kolb T; Benckendorff J; Möller P; Barth TFE; Marienfeld RB
Neoplasia; 2023 Apr; 38():100884. PubMed ID: 36812781
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of resected pathological stage I lung adenocarcinoma: evaluating subtypes and PD-L1/CD155 expression.
Nishizawa N; Shimajiri S; Oyama R; Manabe T; Nemoto Y; Matsumiya H; Honda Y; Taira A; Takenaka M; Kuroda K; Tanaka F
Sci Rep; 2023 Dec; 13(1):21687. PubMed ID: 38065981
[TBL] [Abstract][Full Text] [Related]
7. The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?
Bulutay P; Firat P; Zeren EH; Erus S; Tanju S; Dilege MŞ
Turk J Med Sci; 2021 Feb; 51(1):204-213. PubMed ID: 33155793
[TBL] [Abstract][Full Text] [Related]
8. Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma.
Tancoš V; Grendár M; Farkašová A; Huťka Z; Mičák J; Kviatkovská Z; Hardman TC; Hardy GAD; Plank L
Pathology; 2020 Aug; 52(5):538-545. PubMed ID: 32586689
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous distribution of PD-L1 expression in the IASLC/ATS/ERS classification of lung adenocarcinoma.
Zhang D; Gao X; Yan Z; He W; Li Q
Int J Clin Oncol; 2022 Jan; 27(1):105-111. PubMed ID: 34613497
[TBL] [Abstract][Full Text] [Related]
10. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
12. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Serra P; Petat A; Maury JM; Thivolet-Bejui F; Chalabreysse L; Barritault M; Ebran N; Milano G; Girard N; Brevet M
Lung Cancer; 2018 Apr; 118():62-68. PubMed ID: 29572005
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas.
Zito Marino F; Rossi G; Montella M; Botti G; De Cecio R; Morabito A; La Manna C; Ronchi A; Micheli M; Salatiello G; Micheli P; Rocco D; Accardo M; Franco R
Am J Surg Pathol; 2020 Mar; 44(3):378-386. PubMed ID: 31688140
[TBL] [Abstract][Full Text] [Related]
15. Pathologic Subtypes of Lung Adenocarcinoma Brain Metastasis Is a Strong Predictor of Survival After Resection.
Casteillo F; Guy JB; Dal-Col P; Karpathiou G; Pommier B; Bayle-Bleuez S; Fournel P; Vassal F; Forest F
Am J Surg Pathol; 2018 Dec; 42(12):1701-1707. PubMed ID: 30222604
[TBL] [Abstract][Full Text] [Related]
16. Spatial distribution of immune checkpoint proteins in histological subtypes of lung adenocarcinoma.
Müller S; Mayer S; Möller P; Barth TFE; Marienfeld R
Neoplasia; 2021 Jun; 23(6):584-593. PubMed ID: 34102454
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung.
Kim M; Chung YS; Kim KA; Shim HS
Lung Cancer; 2019 Nov; 137():129-135. PubMed ID: 31586770
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analysis of programmed death-ligand 1 testing in tumor cells of 325 patients with non-small cell lung cancer: Its predictive and potential prognostic value.
Farkašová A; Tancoš V; Kviatkovská Z; Huťka Z; Mičák J; Scheerová K; Szépe P; Plank L
Cesk Patol; 2018; 54(3):137-142. PubMed ID: 30445818
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L
Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388
[TBL] [Abstract][Full Text] [Related]
20. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
Ng Kee Kwong F; Laggner U; McKinney O; Croud J; Rice A; Nicholson AG
Histopathology; 2018 May; 72(6):1024-1032. PubMed ID: 29323731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]